Summary-We report the primary analysis of the safety and efficacy of the MRKad5 gag/pol/ nef HIV-1 sub-type B vaccine in South Africa (SA), where the major circulating clade is sub-type C.
Introduction
South Africa (SA), the country with the largest number of people infected with HIV-1 (5.7 million) 1 and an HIV-1 prevalence of 11% in the general population 2 is in dire need of a biomedical intervention to prevent HIV-1 infection. The HVTN 503 or Phambili (Zulu for "forward!") study was the second phase IIb HIV vaccine test-of-concept study to evaluate the efficacy of the MRKAd5 HIV-1 gag/pol/nef sub-type B vaccine. This vaccine was designed to elicit T-cell mediated immune responses capable of providing complete or partial protection from HIV-1 infection or a decrease in viral load post-acquisition [3] [4] [5] [6] [7] [8] [9] . The Ad5 vaccine was shown to elicit immune responses in participants regardless of Ad5 serostatus 10 . With promising safety and immunogenicity data from earlier clinical studies 10, 11 , the Step test-of-concept of study 12 was designed to assess the efficacy of this vaccine in regions of the world where the predominant circulating sub-type is clade B. The Phambili study was designed soon after to test the vaccine in a clade C region of the world 13, 14 , in populations with high levels of pre-existing immunity to Ad5 15, 16 . Crossclade T cell immunity to HIV-1 gag, pol and nef genes had been demonstrated in both HIV-1 infected and Clade B vaccinated HIV seronegatives, providing an immunization rationale for the trial in SA 17, 18 . Enrollment and vaccinations in the Phambili study, were stopped in September 2007 following the Step study's interim analysis, which found that the vaccine did not protect against HIV-1 infection or reduce early viral load in those who acquired infection. In an exploratory analysis of Step data, the risk of HIV-1 infection also appeared to be higher in a sub-group of male vaccine recipients, those who were Ad5 seropositive or uncircumcised 12 . We report our findings from the Phambili study on HIV-1 acquisition and disease progression as well as describe and investigate factors associated with HIV-1 acquisition as a means of guiding future biomedical interventions directed at reducing HIV-1 acquisition.
Methods

Study Design and Population
The study, a two-arm, double-blind, placebo controlled randomized clinical trial, was initiated in January 2007 and designed to enroll 3000 healthy HIV uninfected, predominantly heterosexual adults between the ages of 18-35 years at 5 sites within SA (Soweto, Cape Town, Klerksdorp-Orkney-Stilfontein-Hartbeesfontein [KOSH], eThekwini, and MEDUNSA). Because of the generalized nature of the HIV-1 epidemic in SA, the only behavioral risk eligibility criterion was being sexually active within the six months prior to enrollment. Pregnant or breastfeeding women were ineligible, and women had to agree to use two methods of contraception (barrier and other effective method e.g. hormonal contraception) to avoid pregnancy from 21 days prior to their first vaccination until one month after their last vaccination.
The study was registered with the Food and Drug Administration (FDA) in the USA; and approved by the SA Medicines Control Council; the Genetically Modified Organism Review Committee of the SA Department of Agriculture; and the ethical review committees and institutional biosafety committees of the University of the Witwatersrand, University of Cape Town, University of Limpopo and the University of KwazuluNatal. Participants provided written informed consent in English or their local language. The trial was registered in clinicaltrials.gov (NCT00413725) and the SA National Health Research Database (DOH-27-0207-1539).
On 19 September 2007, enrollment and vaccinations were halted based on the interim analyses of the Step study 12 , and in October 2007, unblinding of participants began, with concomitant HIV-1 testing, risk evaluation and counselling. After unblinding, follow-up visits were changed from every six to every three months for more frequent HIV-1 testing and risk reduction counseling, and are ongoing.
Randomization
Randomization was 1:1 between vaccine and placebo and stratified by site and gender. The randomization sequence was based on computer-generated random numbers and provided to site pharmacists by a central statistical and data monitoring center (SDMC).
Masking
The participants, study team and laboratory were blinded to treatment allocation.
Products and Procedures
The study product, MRKAd5 HIV-1 gag/pol/nef vaccine, manufactured by Merck and Co., Inc, has been described elsewhere 12 , but in brief, the vaccine was given as a dose of 1.5×10 10 Ad viral genomes/1mL; the placebo was a 1ml solution of the vaccine diluent with no Ad5 vector. Study products were administered by intramuscular injection on a 0, 1, 6 month schedule. Serum samples were obtained at enrolment for Ad5 neutralizing antibody titres 19 and herpes simplex virus, type 2 (HSV-2) serology 20 . Clinical assessments and risk reduction counseling occurred at every visit. Before each vaccination, pregnancy was excluded. Full Blood Count (FBC) with differential, platelet counts and alanine aminotransferase values (ALT) were obtained 14 days following first vaccination.
An assessment of HIV-1 risk behaviors in the previous six months was administered at screening and every six months prior to termination of enrolment and vaccinations; after participant unblinding, these assessments were performed every three months using a threemonth time frame for behaviors. At screening, men were also assessed for circumcision status by physical exam. HIV-1 prevention interventions were provided to all participants throughout the trial including: risk reduction counseling, provision of male condoms; partner and couple HIV testing and counseling; male circumcision 21 ; STI management; and postsexual exposure antiretroviral prophylaxis.
Before enrollment and vaccination were suspended, HIV-1 testing was done on blood drawn on the day of first vaccination, week 12, week 30, and every six months thereafter using an algorithm that distinguishes true infection from vaccine-induced seropositivity: an initial positive test result is confirmed by a second blood draw, which includes HIV RNA detection. HIV-1 testing occurred at unblinding and subsequently every three months. HIV-1 infected participants underwent physical examination, post-test counseling and regular blood draws for monitoring of viral load and CD4 count and were referred for medical care including ART.
Vaccine immunogenicity was measured on a subset of participants in the HVTN laboratory using a validated IFN-γ ELISPOT assay using two panels of peptide pools, Clade B vaccine-matched and Clade C potential T-cell epitopes (PTE-C), in previously cryopreserved PBMCs 22 . The primary immunogenicity assessment was conducted on samples obtained by venipuncture at Week 8, 4 weeks following the second vaccination from the first 186 participants enrolled (93 vaccinees/93 placebo recipients) who were HIV-1 antibody negative at the Week 12 visit; had received the second study injection, and whose thawed PBMC had ≥ 66% cell viability 23 .
Study Objectives and Endpoints
The objectives of the study were to assess the safety, tolerability and efficacy of the MRKAd5 vaccine. The study had two co-primary efficacy endpoints: acquisition of HIV-1 infection and HIV-1 viral-load setpoint in participants who become HIV-1 infected.
Statistical Analysis
This was an event-driven trial, designed to accrue at least 120 per-protocol events among 3000 participants to provide 80% power to detect a vaccine efficacy (VE) against infection of at least 45% and/or at least a 0.75 log 10 copies per mL reduction in the mean viral-load setpoints of vaccinees vs. placebos. VE was defined as 100 × [1 − (vaccine infection rate/ placebo infection rate)]. Viral-load setpoint was defined as the geometric mean of HIV plasma viral load (Roche COBAS Amplicor Monitor HIV-1 Standard, Roche Diagnostics, Location) measurements at ~2 months through ~3 months post-diagnosis. Results from earlier time points were used when both month 2 and 3 values were missing.
The two endpoints were assessed independently with two-tailed significance tests stratified by gender. A Hochberg multiplicity adjustment was applied to the p-values to adjust for the two endpoints 24 . Follow-up for HIV infection is through 31 August 2009, with viral load and CD4 data through 15 January 2010 to allow sufficient time to calculate viral-load setpoint.
The efficacy endpoint analyses were modified intent-to-treat (MITT). The original study design called for a per-protocol (PP) efficacy analysis, limiting to participants who received at least two vaccinations and were sero-negative at the week 12 visit. However, due to the early stopping and consequent reduction in the PP and overall sample size, the analysis plan was changed to MITT prior to unblinding. The MITT population includes all vaccinated participants apart from those diagnosed as HIV-1 infected on the day of first vaccination.
Safety analyses included all randomized participants who received at least one study injection. Differences between treatment arms for reactogenicity and adverse events were assessed with Fisher's exact tests. Differences in STI rates were assessed with tests of homogeneity of the Poisson rates.
For HIV-1 infection, a Cox proportional hazards model was used to estimate the infection hazard ratio for vaccine:placebo (HR) adjusted for gender with Wald-based 95% confidence interval (CI). Time to HIV-1 infection for infected participants was defined as the time from first study injection to the midpoint between the last plasma HIV-1 RNA negative and first RNA positive test; for uninfected participants it was the time from first study injection to last day of study follow-up. Cumulative incidence plots of time to HIV-1 infection by treatment and gender are provided for illustration. To assess changes in the HR over time, the point estimate and 95% confidence bands for the instantaneous hazard ratio were plotted 25 . Cox proportional hazards models were used to assess other predictors of HIV-1 infection: age (in quartile groups), baseline Ad5 titre (both 18 and 200 cut-points assessed), number of vaccinations received (placebo arm = 0), baseline HSV-2 seropositivity, baseline behavioral risk factors (except for having an HIV positive partner and exchange of sex, which could not be tested due to small numbers), baseline circumcision status (men), and use of hormonal contraceptives at baseline (women). Cox models were also used to evaluate time to CD4 decline <350, a typical ART-initiation guideline.
For viral load setpoint, values below the limit of detection (<400) were set to 400 copies/ mm 3 . The difference in the distributions of viral load setpoint between vaccine and placebo groups were assessed with a Wilcoxon rank sum test stratified by gender.
Funding
The study was funded by grants from the National Institute of Allergy and Infectious Diseases to the HIV Vaccine Trials Network -Core, #5U01 AI068614, Lab, 5U01 AI068618, and SDMC 5U01 AI068635; and to the clinical study sites: the PHRU Soweto: 5U01 AI069453; Cape Town: 5U01 AI069519; and KOSH/Klerksdorp: 5U01 AI069469; as well as Merck & Co., Inc. The South African AIDS Vaccine initiative (SAAVI) provided support to the clinical trial sites.
Results
We enrolled 801 participants between 24 January 2007 and 19 September 2007, before enrolment and vaccinations were discontinued, in five sites in SA (Figure 1 ). Of those enrolled, 360 (44.9%) were women (Table 1) , and two thirds (522) were under the age of 25. Nearly 20% (154) of participants had baseline Ad5 antibody titres ≤18 and 55.6% (445) had Ad5 antibody titres of >200. At enrollment, 129 men (29.3%) were circumcised (61 on the vaccine arm and 68 on the placebo arm). An additional 109 men were circumcised postenrollment (52 vaccine, 57 placebo); half of these occurred pre-unblinding (26 vaccine, 29 placebo). HSV-2 prevalence at baseline was significantly higher in women than in men, (177/360=49.2% vs 72/441=16.3%, respectively, p<0.001). Baseline demographic and HIV risk behaviors were similar between study arms except for women reporting drinking or taking drugs during sex in the 6 months prior to screening (26/178=14.6% of vaccinees and 14/182=7.7% of placebo recipients, p = 0.04). Our cohort was predominantly heterosexual with 457/801=57.1% of participants reporting unprotected vaginal or anal sex as a risk factor. Men were more likely than women to report more than one sexual partner (247/441=56.0% vs 56/360=15.6%, respectively, p<0.001) and to report having a casual or anonymous partner (209/441=47.4% vs 40/360=11.1%, p<0.001). Most participants (304/441=68.9% of men and 302/360=83.9% of women) had a main partner, with 349/606=57.6% of those with a main partner regularly living apart. Less than 10% of both men and women reported having an HIV positive partner, exchanging sex for money or gifts, being forced to have sex, or being diagnosed with an STI and few women reported heavy drinking (Table 1 ). In total, 216 (27.0%) received one study injection, 529 (66.0%) two injections, and 56 (7.0%) three injections. There were no differences between the treatment arms in the number of injections received or in reasons for discontinuation of vaccination. Overall, 63 (7.9%) participants withdrew from the study by 31 August 2009 (Figure 1) , the proportion being similar between treatment arms. Post unblinding, more participants in the placebo vs vaccine arm (n=13 vs 6) refused further participation.
Vaccines were well tolerated. Adverse events, local and systemic reactogenicity and in Table 2 and pregnancies are reported in web appendix 3. Self reported STI rates were similar between vaccine and placebo arms over the entire study period (7.5 vs 9.8 per 100 person-years) as well as over the pre-and post-unblinding periods (9.9 vs 9.6 and 7.7 vs 9.9 per 100 person-years). Women were more likely than men to report an STI (11.1 vs 6.7 per 100 person-years, p=0.007).
At four weeks following the 2 nd vaccination, 83/93=89.2% of vaccinees had developed an IFN-γ secreting T cell response to Clade B peptides and 72/93=77.4% to Clade C peptides (Table 3) . For Clade B, Gag-specific responses were highest (74/93=79.6%); for Clade C, Pol-specific responses were highest (65/93=69.9%). All Clade C responders also had a Clade B response. Among responders to both Clades B and C, the overall magnitude of response to the Clade B vaccine-matched panel was significantly higher than to Clade C PTE panel; the same pattern held for responses to individual antigens (Table 3) . Although not statistically different, vaccinees seronegative for Ad5 (titre ≤18) at baseline tended to demonstrate consistently higher response rates for both clades, overall and by gene, than those Ad5 seropositive (Table 3) . Among responders, the Ad5 seronegative vaccinees also had a greater magnitude of response than those Ad5 seropositive for both clades overall (p = 0.004 for B and 0.007 for C), for Clade B Nef and Pol (p = 0.049 and = 0.002), and Clade C Pol (p = 0.01).
There was no evidence of VE (Figure 2 ): the treatment HR adjusted for gender was 1.25 (95% CI: 0.76, 2.05). Accounting for the time at which participants were notified of their treatment assignment did not alter this finding: the HR adjusted for unblinding time was 1.15 (95% CI: 0.69, 1.90). The treatment HR was higher in the 6 months (26 weeks) after first vaccination, but this finding was not significant as can be seen in Web appendix Figure  1 which illustrates the log instantaneous HR for treatment over time since first vaccination. HIV incidence was similar between vaccine and placebo arms (4.54 vs 3.70/100 personyears, n=34 vs 28, Web appendix 1). The majority of these infections were among women (n=42, Figure 2 ) with high HIV-1 incidence rates both in the vaccine arm (6.79) and placebo arm (5.86).
In multivariate Cox proportional hazard models, gender, age, HSV-2 and the interaction of gender and HSV-2 were significant predictors of HIV-1 infection (Table 4) . Baseline Ad5 titre, categorized using either 18 or 200 as a cut-point, was not a significant predictor of HIV-1 infection and adjusting for Ad5 had little effect on the treatment HR; (HR= 1.24 -1.31, depending on model). The number of vaccinations and behavioural risk factors were also not significant predictors of infection. Ad5 titre, gender, age or HSV-2 did not modify the treatment HR, nor did the effect of age and Ad5 titre differ by gender.
HSV-2 increased the risk of HIV-1 in men but not in women (Table 4) . For men, HSV-2 increased the risk of infection more than 5-fold (5.23, 95% CI: 2.09, 13.10). For those HSV-2 negative at baseline, women had an increased risk of HIV-1 compared to men (HR 4.60; 2.16, 9.79). In an analysis restricted to women, there were no significant predictors of HIV-1 infection. In multivariable analysis for men (Web appendix Table 2 ), HSV-2 (HR 4.90, 95% CI 2.03, 11.80) and having a main partner but living apart regularly (HR 3.61, 95% CI 1.31, 9.99) were associated with HIV-1 infection; neither Ad5 titre nor circumcision were significant. HSV-2 status post-enrollment was not assessed; among 31 participants who acquired HIV-1 who were HSV-2 seronegative at enrollment, 22 either did not change HSV-2 status (19) or acquired HSV-2 prior to HIV-1 infection (3), and all nine remaining participants were identified as HSV-2 and HIV-1 positive at the same visit. Viral-load setpoint was calculated for 61 of the HIV-1 infected participants. One woman on the vaccine arm was excluded from the viral-load setpoint analysis because of a six month delay in confirming infection. There was no significant difference in the distribution of viral load setpoint between the vaccine arm (geometric mean titre 20,483 copies/mL, N=33) and the placebo arm (34,032 copies/mL, N=28) (Figure 3, p=0.39, stratified by gender) . Women tended to have lower viral-load setpoints than men (geometric mean 19,642 vs 45,438 copies/mL), which was not statistically significant (p = 0.15). Women who received vaccine (n=21) tended to have lower viral-load setpoints than women on the placebo arm (n=20) although this was not statistically significant (11,401 vs 34,773; p=0.16) . Participants with baseline Ad5 titre > 18 (n=50) tended to have higher viral-load setpoint than those ≤ 18 (n=11), (31,924 vs 9,924), but this too, was not statistically significant (p =0.12).
Neither of the p-values for the co-primary endpoints of HIV-1 infection and viral-load setpoint were statistically significant, adjusted p's=0.39. Seven infected participants (3 vaccine, 4 placebo) started ART, all after the 3 rd month visit post HIV-1 diagnosis. Two women with CD4 counts above 350 initiated ART to prevent mother-to-infant transmission and data from these women were censored at 3 months and 1 year, respectively. Treatment was not a significant predictor of CD4 decline to less than 350 overall or among men, but among women, vaccinees were at significantly lower risk of this event than placebos: HR=0.33 (95% CI: 0.12, 0.91) (Web appendix Figure 2) . No other significant predictors of time to CD4 count less than 350 were found among baseline covariates considered: site, Ad5 titre, age quartiles, HSV-2 and their interactions with treatment.
Discussion
This study agrees with the Step findings that the MRKAd5 HIV-1 vaccine did not prevent HIV-1 infection or lower early viral load in either Ad5 sero-positive or -negative vaccinees. However, Phambili had limited ability to assess the vaccine due to the discontinuation of enrollment and vaccination, possible changes in risk behavior after unblinding, and the limited number of infections particularly those occurring close to vaccination. This lack of vaccine effect is despite the relatively high frequency and magnitude of HIV-1 specific T cell responses measured by INF-γ ELISPOT to both clade B and C antigens. Most vaccinees developed an immune response to both Clades B and C, although the responses were greater to the vaccine-matched Clade B peptides. Although the vaccine was immunogenic in this and previous studies 26 , the responses elicited did not translate to vaccine efficacy.
The high incidence of HIV-1 in women permitted the first evaluation of VE among heterosexual women and highlights the pressing need to find effective preventive interventions for women. There was no evidence of increased risk of HIV-1 infection among vaccinated participants compared to placebo. There was also no such evidence among Ad5 seropositive women or men or among uncircumcised men.
Although our results differ from Step, the premature interruption of the study, discontinuation of vaccinations, and unblinding may have affected risk behaviour, impacted on our statistical power to show these associations; or may have altered susceptibility to infection. In addition, the men in our study were predominantly heterosexual, therefore risk factors would have differed from the predominantly homosexual population studied in Step.
Prior HSV-2 infection has been associated with increased HIV-1 infection [27] [28] [29] [30] and was associated with increased HIV-1 acquisition among men who have sex with men in the Step trial. In Phambili, prior HSV-2 infection was associated with HIV-1 infection among heterosexual men but not women. The finding in women that HIV-1 risk was not associated with prevalent HSV-2 has been documented previously 31 . The lack of association between oral or injectable hormonal contraception use at baseline and HIV-1 acquisition is consistent with other studies. 32 In men, HSV-2 status and living apart from the main partner were associated with HIV infection, and interventions addressing these factors need to be studied.
The lower viral-load setpoint and slower CD4 decline observed in vaccinated women may indicate a vaccine effect on disease progression, although, because enrolment in the study was halted prematurely, this study was not powered to detect this effect. Pre-existing immunity to the vaccine vector may alter VE. Further studies are required to understand the interplay between vaccination and these factors, including gender. A study of sexual partners of Phambili participants to provide new insights on the natural history of HIV infection and transmission dynamics in this population has been initiated.
Stratification by sex should be considered in future vaccine efficacy trials, to examine the effects of HIV-1 vaccines on gender. Longer follow-up of incident infections is warranted to assess the effects of vaccination on disease progression.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. Behavioral risk data are based on self-reported behaviour within 6 months prior to screening. Apart regularly from main partner is defined as living in a different location or partner regularly away from home for 3 or more days per week or for men, being away from home for 3 or more days per week. Sexually transmitted infection (STI) is based on participant self-report of a STI diagnosis. Heavy drinking is defined as having >5 drinks per day on at least 10 days within the six month reporting period.
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Table 3
Interferon-γ secreting T cell responses by ELISPOT in vaccine recipients at Week 8 
